{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:37:40Z","timestamp":1793342260626,"version":"4.5.0"},"reference-count":71,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The treatment landscape for hematologic malignancies has changed since the recent approval of highly effective chimeric antigen receptor T-cell therapies (CAR-T). Moreover, more than 600 active trials are currently ongoing. However, early enthusiasm should be tempered since several issues are still unsolved and represent the challenges for the coming years. The lack of initial responses and early relapse are some hurdles to be tackled. Moreover, new strategies are needed to increase the safety profile or shorten the manufacturing process during CAR-T cells therapy production. Nowadays, most clinically evaluated CAR-T cells products are derived from autologous immune cells. The use of allogeneic CAR-T cells products generated using cells from healthy donors has the potential to change the scenario and overcome many of these limitations. In addition, CAR-T cells carry a high price tag, and there is an urgent need to understand how to pay for these therapies as many of today\u2019s current payment systems do not feature the functionality to address the reimbursement gap. Finally, the clinical experience with CAR-T cells for solid tumors has been less encouraging, and development in this setting is desirable.<\/jats:p>","DOI":"10.3390\/ijms232113332","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T03:36:44Z","timestamp":1667360204000},"page":"13332","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon"],"prefix":"10.3390","volume":"23","author":[{"given":"Massimo","family":"Martino","sequence":"first","affiliation":[{"name":"Stem Cell Transplant and Cellular Therapies Unit, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC 587, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Naso","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant and Cellular Therapies Unit, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC 587, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Loteta","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant and Cellular Therapies Unit, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC 587, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9400-5897","authenticated-orcid":false,"given":"Filippo Antonio","family":"Canale","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant and Cellular Therapies Unit, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC 587, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant and Cellular Therapies Unit, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC 587, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Alati","sequence":"additional","affiliation":[{"name":"Hematology Unit, Great Metropolitan Hospital \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[{"name":"Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-5875","authenticated-orcid":false,"given":"Davide","family":"Nappi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Bone Marrow Transplantation (CBMT), Ospedale di Bolzano, 39100 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7456-4197","authenticated-orcid":false,"given":"Anna","family":"Gaimari","sequence":"additional","affiliation":[{"name":"Immunotherapy, Cell Therapy and Biobank (ITCB), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6846-5435","authenticated-orcid":false,"given":"Fabio","family":"Nicolini","sequence":"additional","affiliation":[{"name":"Immunotherapy, Cell Therapy and Biobank (ITCB), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-5743","authenticated-orcid":false,"given":"Massimiliano","family":"Mazza","sequence":"additional","affiliation":[{"name":"Immunotherapy, Cell Therapy and Biobank (ITCB), IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-8538","authenticated-orcid":false,"given":"Sara","family":"Bravaccini","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-4157","authenticated-orcid":false,"given":"Daniele","family":"Derudas","sequence":"additional","affiliation":[{"name":"S.C. di Ematologia e C.T.M.O., Ospedale Oncologico di Riferimento Regionale \u201cA. Businco\u201d, 09121 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-4210","authenticated-orcid":false,"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Scientific Directorate IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-5436","authenticated-orcid":false,"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[{"name":"Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.12688\/f1000research.27217.2","article-title":"Cancer T-cell therapy: Building the foundation for a cure","volume":"9","author":"Kamb","year":"2020","journal-title":"F1000Research"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Martino, M., Alati, C., Canale, F., Musuraca, G., Martinelli, G., and Cerchione, C. (2021). A Review of Clinical Outcomes of CAR T-Cell Therapies forB-Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042150"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Martino, M., Canale, F.A., Alati, C., Vincelli, I.D., Moscato, T., Porto, G., Loteta, B., Naso, V., Mazza, M., and Nicolini, F. (2021). CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13112639"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s40425-019-0741-7","article-title":"CAR-T cell therapy: A potential new strategy against prostate cancer","volume":"7","author":"Schepisi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_5","unstructured":"(2018, March 05). FDA Approves Tisagenlecleucel for Adults with Relapsed or Refractory Large B-Cell Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma."},{"key":"ref_6","unstructured":"(2022, August 09). FDA Approves Axicabtagene Ciloleucel for Large B-Cell Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma."},{"key":"ref_7","unstructured":"(2022, August 09). First Two CAR-T Cell Medicines Recommended for Approval in the European Union. Available online: https:\/\/www.ema.europa.eu\/en\/news\/first-two-car-t-cell-medicines-recommended-approval-european-union."},{"key":"ref_8","unstructured":"(2022, August 09). FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma."},{"key":"ref_9","unstructured":"(2022, August 09). FDA Approves Idecabtagene Vicleucel for Multiple Myeloma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.23736\/S0031-0808.20.04121-X","article-title":"BCMA-targeting approaches for treatment of multiple myeloma","volume":"63","author":"Chen","year":"2021","journal-title":"Panminerva Medica"},{"key":"ref_11","first-page":"37","article-title":"CAR T cells targeting options in the fight against multiple myeloma","volume":"63","author":"Juan","year":"2021","journal-title":"Panminerva Medica"},{"key":"ref_12","unstructured":"(2022, August 09). FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1200\/JCO.2021.39.15_suppl.7002","article-title":"Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL)","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1200\/JCO.2021.39.15_suppl.8015","article-title":"Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"39","author":"Frigault","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2019-126218","article-title":"CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: A phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"ref_26","first-page":"1","article-title":"A retrospective comparison of CD19 single and CD19\/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"10","author":"Wang","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2021.39.15_suppl.2508","article-title":"Safety and efficacy of a novel an-ti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed\/refractory (r\/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy","volume":"39","author":"Liang","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cam4.3624","article-title":"Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma","volume":"10","author":"Yan","year":"2020","journal-title":"Cancer Med."},{"key":"ref_30","first-page":"391","article-title":"Anti-CD22 CAR T cells in ALL","volume":"17","author":"Killock","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.2020009432","article-title":"CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR\u2013refractory large B-cell lymphoma","volume":"137","author":"Baird","year":"2021","journal-title":"Blood"},{"key":"ref_32","unstructured":"(2022, August 09). BCMA-Specific CAR T-Cells Combined with a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03502577."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2015","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1080\/10428194.2022.2043299","article-title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","volume":"63","author":"Tettamanti","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","article-title":"Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination with Ibrutinib or Acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J. Immunother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","article-title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","volume":"131","author":"Legut","year":"2018","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"605766","DOI":"10.3389\/fimmu.2021.605766","article-title":"Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"611710","DOI":"10.3389\/fimmu.2020.611710","article-title":"How to Combine the Two Landmark Treatment Methods\u2014Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41409-019-0604-3","article-title":"The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia","volume":"54","author":"Jacoby","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1200\/JCO.2018.36.15_suppl.3041","article-title":"Which is better in CD19 CAR-T treatment of r\/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process","volume":"36","author":"Lu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_44","unstructured":"DeAngelo, D., Ghobadi, A., Park, J., Dinner, S., Mannis, G., Lunning, M., Khaled, S., Fathi, A., Gojo, I., and Wang, E. (2017). Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET study). J. Immunother. Cancer, 5."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1182\/blood-2019-131399","article-title":"A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy","volume":"134","author":"Nasta","year":"2019","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"627764","DOI":"10.3389\/fimmu.2021.627764","article-title":"Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction","volume":"12","author":"Hong","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"477.e1","DOI":"10.1016\/j.jtct.2021.03.004","article-title":"Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma","volume":"27","author":"Banerjee","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e19506","DOI":"10.1200\/JCO.2022.40.16_suppl.e19506","article-title":"Role of anakinra in the management of icans after CAR T-cell therapy for lymphoma","volume":"40","author":"Munugala","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","article-title":"Granulocyte\u2013macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators","volume":"294","author":"Sachdeva","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated k light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2019-121751","article-title":"A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia","volume":"134","author":"Yang","year":"2019","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3389\/fimmu.2020.01941","article-title":"Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma","volume":"11","author":"Jackson","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: Results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12026-020-09119-7","article-title":"Paving the way towards universal treatment with allogenic T cells","volume":"68","author":"Townsend","year":"2020","journal-title":"Immunol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1002\/ajh.25399","article-title":"Allogeneic CAR T cell therapies for leukemia","volume":"94","author":"Qasim","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex Genome-Edited T-cell Manufacturing Platform for \u201cOff-the-Shelf\u201d Adoptive T-cell Immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: Challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: Functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor\u2013Modified T Cells in Solid Tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: Past, present, and the future","volume":"168","author":"Swanton","year":"2017","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00262-018-2150-z","article-title":"Quantifying tumor-infiltrating immune cells from transcriptomics data","volume":"67","author":"Finotello","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_68","unstructured":"Mistichelli, J. (1984). Diagnosis Related Groups (DRGs) and the Prospective Payment System: Forecasting Social Implications, Georgetown University."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2307\/258330","article-title":"Diagnosis-related groups: Product line management within hospitals","volume":"11","author":"Fetter","year":"1986","journal-title":"Acad. Manag. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.clml.2017.05.018","article-title":"Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model. Clin","volume":"17","author":"Martino","year":"2017","journal-title":"Lymphoma Myeloma Leuk."},{"key":"ref_71","first-page":"109","article-title":"The promise--and peril--of integrated cost systems","volume":"76","author":"Cooper","year":"1998","journal-title":"Harv. Bus. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/21\/13332\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:08:51Z","timestamp":1760144931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/21\/13332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":71,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ijms232113332"],"URL":"https:\/\/doi.org\/10.3390\/ijms232113332","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}